Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash Flows From Operating Activities
Net income (loss)	$ 17,624	$ (43,653)
Adjustments to reconcile net income (loss) to net cash and cash equivalents (used in) provided by operating activities:
Stock-based compensation	15,031	10,862
Deferred taxes	(3,394)	(13,628)
Depreciation and amortization	44,597	44,081
Acquired in-process research and development ("IPR&D")	0	1,151
Non-cash operating lease expense	888	0
Non-cash interest	2,970	2,963
Contingent consideration fair value adjustment	(559)	2,134
Asset impairment charges	0	574
Gain on sale of ANDAs	0	(750)
Changes in operating assets and liabilities, net of acquisition:
Accounts receivable, net	(13,404)	(11,907)
Inventories	(1,236)	(14,164)
Prepaid expenses and other current assets	(636)	2,617
Accounts payable	4,772	(5,027)
Accrued royalties	(2,668)	360
Current income taxes payable, net	4,426	(111)
Accrued government rebates	(51)	3,253
Returned goods reserve	(1,961)	(1,818)
Accrued expenses, accrued compensation, and other	7,820	(3,740)
Net Cash and Cash Equivalents Provided by (Used in) Operating Activities	74,219	(26,803)
Cash Flows From Investing Activities
Acquisition of Novitium Pharma LLC, net of cash acquired	0	(33)
Acquisition of product rights, intangible assets, and other related assets	(7,143)	(7,575)
Acquisition of property and equipment, net	(6,589)	(5,738)
Proceeds from the sale of long-lived assets	0	750
Net Cash and Cash Equivalents Used in Investing Activities	(13,732)	(12,596)
Cash Flows From Financing Activities
Payments on borrowings under credit agreements	(2,250)	(2,250)
Series A convertible preferred stock dividends paid	(1,219)	(1,218)
Proceeds from stock option exercises and ESPP purchases	7,027	690
Proceeds from public offering, net of transaction expenses	80,555	0
Treasury stock purchases for restricted stock vests	(4,756)	(1,840)
Net Cash and Cash Equivalents Provided by (Used in) Financing Activities	79,357	(4,618)
Net Change in Cash, Cash Equivalents, and Restricted Cash	139,844	(44,017)
Cash, cash equivalents, and restricted cash, beginning of period	53,234	105,301
Cash, cash equivalents, and restricted cash, end of period	193,078	61,284
Reconciliation of cash, cash equivalents, and restricted cash, beginning of period
Cash and cash equivalents	193,078	56,281
Restricted cash	0	5,003
Cash, cash equivalents, and restricted cash, end of period	193,078	61,284
Supplemental disclosure for cash flow information:
Cash paid for interest, net of amounts capitalized	23,426	14,028
Cash paid for income taxes	930	156
Right-of-use assets obtained in exchange for lease obligations	4,499	0
Supplemental non-cash investing and financing activities:
Acquisition of product rights included in accounts payable	0	1,000
Property and equipment purchased and included in accounts payable	$ 247	$ 204